1. Introduction {#s0005}
===============

Aging is accompanied by a universal, gradual decline in the integrity and functionality of organs and tissues. While every organism, organ, tissue, or cell population is affected by aging differently, the outcome is universally accompanied by a deterioration in well-being ([@bb0310]). The skeletal system, which is an active, responsive and dynamic tissue, is no exception ([@bb0285]). In fact, aging is the major risk factor for osteoporosis development ([@bb0215]; [@bb0095]). The specific mechanisms underlying age-related bone loss remain incompletely defined, but are crucial to understand. Bone is a heterogeneous tissue made up of extracellular matrix (ECM) and different cell populations including mesenchymal stem cells (MSCs), pre-osteoblasts, osteoblasts, osteocytes, bone lining cells, osteoclasts, a complex vasculature system, and the hematopoietic system ([@bb0465]; [@bb0315]; [@bb0320]; [@bb0460]; [@bb0325]; [@bb0250]). MSCs make up a small percentage of bone cells, but play a vital role in bone modeling and remodeling, fracture repair, and bone aging ([@bb0475]; [@bb0165]). The balance between osteogenic and adipogenic MSC differentiation in bone marrow is tightly regulated and imperative for bone health ([@bb0095]; [@bb0490]; [@bb0510]). The literature reports a skewed differentiation pattern of bone marrow mesenchymal stem cells (BMSCs) with age, with both an overall decline in numbers and a shifting from osteogenic to more adipogenic differentiation ([@bb0290]; [@bb0245]; [@bb0080]). According to Infante et al. ([@bb0215]), this shift from osteogenesis to adipogenesis in the aging bone marrow MSC population is orchestrated by a number of factors including transcription factors, miRNAs, autophagy levels, cell-extrinsic factors, and epigenetic modifications of DNA.

One such factor of interest is kynurenine (KYN), a primary active metabolite of tryptophan (TRP) that is produced by ROS-mediated oxidation and the action of indoleamine 2,3 dioxygenase-1 or -2 (IDO1 or IDO2) ([@bb0345]; [@bb0435]; [@bb0055]; [@bb0305]; [@bb0340]). A high KYN/TRP ratio is correlated with low bone mineral density (BMD) ([@bb0015]). The essential amino acid TRP is crucial for anabolic BMSCs pathways, including those supporting cell proliferation and differentiation, but KYN inhibits these pathways ([@bb0130]). KYN is thought to mainly act through the aryl hydrocarbon receptor (AhR) ([@bb0350]; [@bb0270]). Once activated, cytoplasmic AhR is transported into the nucleus where it binds the aryl hydrocarbon receptor nuclear translocator (ARNT) and acts as a transcription factor for a wide array of genes ([@bb0370]; [@bb0035]). We recently tested the hypothesis that a high KYN/TRP ratio mimics the aged bone environment and leads to decreased bone mass in mice, showing that a low TRP/high KYN diet leads to significant bone loss and high marrow adiposity in mice, resembling an aged bone phenotype ([@bb0175]; [@bb0425]). We also recently reported elevated KYN concentrations in the bone marrow of aged humans ([@bb0255]).

KYN\'s negative effects on the skeletal system may be mediated by cytokine and epigenetic factors that impact BMSCs. Stromal cell-derived factor 1 (SDF-1 or CXCL12) ([@bb0070]; [@bb0185]; [@bb0365]) is implicated in myriad stem cells functions including cellular proliferation, differentiation, migration, and homing to niche sites ([@bb0090]; [@bb0050]; [@bb0555]; [@bb0295]; [@bb0060]). CXCL12 has multiple splice variants, the most common of which are CXCL12α and CXCL12β ([@bb0565]). Both isoforms act mainly through CXCR4 and CXCR7 (i.e., atypical chemokine receptor 3 \[ACKR3\]) receptors to achieve various downstream effects ([@bb0430]; [@bb0415]; [@bb0450]). We previously reported that CXCL12 levels decline in bone marrow interstitial fluid with aging, while increasing in the peripheral circulation, which correlates with deteriorating bone health in older subjects ([@bb0070]; [@bb0395]). Our group and others have reported that CXCL12 is important for osteogenic differentiation primarally by augmenting the pro-osteogenic effects of BMP-2. CXCR4 signaling is required for the activation of the BMP-2R and increases BMP-2 mediated osteogenesis ([@bb0555]; [@bb0190]; [@bb0200]). Additionally, targeted deletion of CXCL12 BMSCs results in reduced trabecular bone content and increased bone marrow adiposity ([@bb0510]). Regarding epigenetic factors, histone deacetylases (Hdacs) are integrally involved in bone homeostasis. Hdacs remove acetyl groups from lysine residues in histones, which changes chromatin structure and in turn affects gene expression altering many signal transduction pathways. Histone deacetylase 3 (Hdac3) is expressed in osteoblasts and plays a critical role in bone development by binding to the osteogenic transcription factor Runx2 to regulate osteoblastic gene expression ([@bb0045]). Conditional deletion of Hdac3 in osteoprogenitor cells (Hdac3-CKO) causes a reduction in osteoblastic activity and produces a low bone mass phenotype with increased BM adipogenesis ([@bb0505]). Another epigenetic factor that influences BMSC behavior is microRNAs (miRNAs) via effects on cell cycle, apoptosis, proliferation, stem cell maintenance, and differentiation ([@bb0240]; [@bb0085]; [@bb0155]) ([@bb0140]) ([@bb0530]; [@bb0480]; [@bb0520]). MiRNAs are \~20 nucleotide RNAs that bind to mRNAs and post-transcriptionally regulate gene expression of the targeted mRNAs. Pre-miRNAs are processed to generate two partially complementary strands, the normally active guide strand and the passenger strand that is typically degraded and inactive. Several miRNAs play an important role in controlling osteogenic and osteoclastogenic differentiation in the bone marrow, making them valuable new diagnostic biomarkers for bone health ([@bb0265]; [@bb0525]; [@bb0275]). We have identified one of these as the passenger strand of the key osteogenic microRNA-29b-1 (miR-29b-1-5p). This novel passenger strand increases with age in human and murine BMSCs ([@bb0205]; [@bb0390]; [@bb0025]; [@bb0280]; [@bb0495]; [@bb0470]; [@bb0300]; [@bb0540]). The guide strand (miR-29b-1-3p) has been extensively documented to be critical in different stages of bone formation and fracture healing ([@bb0280]; [@bb0300]; [@bb0500]). Of interest miR-29b-1-3p (and other miR-29 family guide strands) target and suppress the CXCL12 regulator dipeptidyl peptidase-4 (DPP4) ([@bb0470]). Therefore, this miRNA is predicted to be central to local bone marrow DPP4 activity and CXCL12 ligand and proteolytic isoform levels. Current studies on miR-29b have focused on the guide strand miR-29b-1-3p (previously miR-29b-1-1) ([@bb0300]). In contrast, the passenger strand miR-29b-1-5p (previously miR-29b-1-1\*) has largely been considered to be a non-functional byproduct of the miR biogenesis process. However, our group has found miR-29b-1-5p to accumulate with aging in human and murine BMSCs ([@bb0040]). Further, when it is expressed in BMSCs it can induce aging-like actions targeting osteogenic genes like the CXCL12 axis, and based on in silico analysis, also Hdac3 ([@bb0040]).

In this paper, we describe three inter-related mechanisms (CXCL12, Hdac3, miR-29b-1-5p) through which KYN affects BMSCs in aging. These pathways are interconnected, and the crosstalk between them appears to be complex and highly regulated. It also appears that KYN\'s effect on CXCL12, miR-29b-1, and Hdac3 are all mediated through binding and nuclear translocation of the xenogeneic AhR.

2. Materials and methods {#s0010}
========================

2.1. Animals {#s0015}
------------

C57BL/6J mice were either provided by the National Institute on Aging (Bethesda, MD, USA) aged rodent colony or purchased from Jackson Laboratories (Bar Harbor, ME, USA). Animals were maintained at Augusta University in the Division of Laboratory Animal Services Facility. All aspects of the animal research were conducted in accordance with the guidelines set by Augusta University Institutional Animal Care and Use Committee (AU-IACUC) under AU-IACUC approved Animal Use Protocols. Mice were maintained on a standard 12-h light -- 12 h dark protocol and permitted water and food ad libitum.

2.2. Isolation and culture of murine BMSCs {#s0020}
------------------------------------------

Murine BMSCs were derived from 3, 6, 11, 18, and 27-month-old male C57BL/6J mice at the Augusta University Stem Cell Core Facility. The BMSC isolation process, as well as the MSC characterization and multi-lineage potential (osteogenic, adipogenic and myogenic) have been described previously ([@bb0185]; [@bb0575]). In brief, six to eight mice of each age were euthanized by CO~2~ overdose followed by thoracotomy. Whole bone marrow aspirates were flushed from femora and tibiae and BMSCs isolated by negative immunodepletion using magnetic microbeads conjugated to anti-mouse CD11b (\#558013) and CD45R/B220 (\#551513) (BD Biosciences Pharmingen, San Diego, CA, USA), CD11c, and plasmacytoid dendritic cell antigen (PDCA)-1 (\#130-092-283 Miltenyi Biotec, Auburn, CA) followed by positive immunoselection using anti-stem cell antigen (Sca)-1 microbeads (\#130-092-529 Miltenyi Biotec, Auburn, CA), according to the manufacturer\'s recommendations. The enriched single-age pooled BMSC populations were maintained in Dulbecco\'s Modified Eagle Medium (\#10-014-CM DMEM; Cellgro, Mediatech, Manassas, VA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (\#S11150 Atlanta Biologicals, Lawrenceville, GA, USA) and used at 60--70% confluency.

To measure mRNA levels of some markers without culturing or plastic adherence, directly isolated BMSCs were derived from young adult (6--8 months) and geriatric (22--24 month-old) female C57BL/6J mice. Long bones (i.e., humeri, femora, tibiae) were dissected from mice and placed into mBMSC medium consisting of alpha MEM (\#41061 Gibco), 20% FBS, 1% antibiotic/antimycotic, and 1% non-essential amino acids \[NEAA\] (\#11140050 Gibco), on ice. BMSCs were then extracted by flushing marrow and filtering through 70 μm cell strainers.

2.3. Isolation and culture of human BMSCs {#s0025}
-----------------------------------------

A direct-isolation procedure was used to rapidly capture human BMSCs directly from bone. Bone marrow aspirates from the proximal tibia (knee replacement surgery), proximal femur (hip replacement surgery) or iliac crest (spinal fusion surgery) were collected as orthopaedic surgical waste under IRB approval in EDTA blood collection tubes. The bone marrow aspirates were then run over a Ficoll gradient to collect the buffy coat within 30 min of collection. CD271 positive (+) hMSCs were then isolated from the nucleated cell layer using CD271 MicroBead Kits (\#130-092-283 Miltenyi Biotec, Auburn, CA) according to the manufacturer\'s protocol to obtain a highly enriched BMSC population within 2 h of bone marrow aspiration. The cells were counted and frozen, or cultured for 1--2 passages prior to cryopreservation for in vitro cell culture studies. The isolated cells were first confirmed by FACS analysis to be positive for CD73, CD90 and CD105 and negative for CD34, CD45 and CD11b. Corresponding isotype control antibodies were used when cells were sorted according to criteria set by the International Society for Cellular Therapy (ISCT) to define hMSCs ([@bb0065]).

Isolating CD271+ cells allows for the direct isolation of BMSCs from orthopaedic patient\'s bone marrow aspirates within 2 h of collection. This is in contrast to the standard BMSCs isolation process that includes 1--2 day plastic adhesion followed by negative and positive selection and an additional 2--3 week passaging. This is now a standard rapid MSCs isolation method that both reduces the complexity of isolation and maintains cell expression profiles as close to in vivo as possible ([@bb0260]; [@bb0005]; [@bb0105]; [@bb0100]; [@bb0410]).

The isolated cells were tested for multilineage properties, i.e., their capacities for osteogenic, adipogenic and chondrogenic differentiation and the expression levels of key genes (qRT-PCR analysis) regulating these differentiation pathways, including Runx2, Osx and ALP (osteogenic), PPARγ, and C/EBPβ and -α (adipogenic), and Sox-9, type I and type II collagen (chondrogenic). Colony-forming unit-fibroblast (CFU-f) assays were performed to calculate the population doubling capacity. CD271+ MSCs were isolated directly from bone marrow aspirates, washed with standard culture medium composed of DMEM medium (\#10-014-CM Corning), 1% antibiotics antimycotics (\#15240-062 AA; Invitrogen) and 15% FBS, with low glucose (1 g/l), transferred to 100 mm culture dish and incubated at 37 °C in a humidified atmosphere in 5% carbon dioxide (CO~2~). After 24 h, the medium with non-adherent cells is removed, and the adherent cells were carefully washed in DPBS (Dulbecco\'s phosphate-buffered saline) (\#SH30028 HyClone) and further expanded in fresh culture medium. Culture-expanded CD271+ MSCs of passage 1--2 were used for in vitro studies.

2.4. KYN preparation and doses {#s0030}
------------------------------

Human and murine BMSCs were treated with different doses (10, 50, and 200 μM) of L-kynurenine (\#K8625 Sigma-Aldrich). Different KYN doses were freshly prepared before administration. Previous data from the literature shows endogenously present KYN levels in the culture media of different cell types is highly variable, ranging from 5 to 60 μM and typically increases with time in culture ([@bb0375]; [@bb0550]). Indeed, utilizing an ELISA kit (\#E4629 Biovision, Milpitas, CA) we identified that commercial DMEM media (\#10-014-CM Corning) itself contains approximately 3--5 μM of KYN (unpublished data). Other researchers have consistently reported various specific dose-dependent effects using wide ranges of KYN doses (10--300 μM) ([@bb0235]; [@bb0545]). Moreover, a recently published paper reported that different doses of KYN (30--500 μM) significantly increased migration in 95D lung cancer cells ([@bb0120]). Taking all these different caveats in consideration, we wanted our data to represent three levels of Kyn: 10 μM (low dose close to that of cell-free media and serum levels), 50 μM (medium dose close to the previously reported conditioned media levels secreted by various cell types in culture), and 200 μM (high dose that exceeds the previously reported in vitro levels, falls within the range of KYN doses previously used in literature, and is similar to the in vivo dose used in our previous Kyn studies ([@bb0425]).

2.5. Osteogenic differentiation assay {#s0035}
-------------------------------------

The ability of culture-expanded MSCs to differentiate into the osteogenic lineage was validated according to earlier described methods ([@bb0185]; [@bb0170]). In brief, cells were plated in 12-well plates at 50000 cells/cm^2^ and cultured in DMEM for 24 h. Culture medium was then aspirated and replaced with StemXVivo Osteogenic/Adipogenic Base Media (\#CCM007 R&D Systems) supplemented with StemXVivo Human Osteogenic Supplement (\#CCM008 R&D Systems). Treatment-containing medium was replaced 2 times per week. The early osteogenic differentiation marker, Alkaline Phosphatase, was assessed in cell culture media after 7 days using an Alkaline Phosphatase Assay Kit (\#ab83369 Abcam). After 3 weeks, osteogenic differentiation was assessed by staining with Alizarin-Red Staining Solution; (\#TMS-008-C Millipore Sigma). The cells were fixed with 10% formalin for 20 min at room temperature (RT) and stained with Alizarin-Red Staining Solution for 20 min at RT. Stained monolayers were visualized by phase-contrast microscopy using an inverted microscope (Nikon, Melville, NY). Differentiation was quantified as previously described ([@bb0440]). In brief, cells were destained using 10% cetylpyridinium chloride (\#855561 Sigma-Aldrich) and collected samples analyzed using a microplate reader at 570 nm.

2.6. Cell density assay {#s0040}
-----------------------

To determine whether KYN affected BMSCs density, we utilized a Crystal violet Assay Kit (\#ab232855 Abcam) according to the manufacturer\'s protocol. In brief, BMSCs were plated in 96 well plates at 5000 cells/well and cultured in DMEM for 24 h. Culture medium was then aspirated and replaced with StemXVivo Osteogenic/Adipogenic Base Media (\#CCM007 R&D Systems) supplemented with StemXVivo Human Osteogenic Supplement (\#CCM008 R&D Systems) with or without different doses of KYN (10, 50, 200 μM). After 3 days, the culture media was removed and the cells were washed and stained with the Crystal Violet Staining solution for 20 min at RT. Then, the staining solution was removed and the remaining stain was solubilized for 20 min with the Solubilization Solution. Finally, the Crystal Violet stain was quantified using a microplate reader at 595 nm.

2.7. Western blotting {#s0045}
---------------------

Whole cell lysates of BMSCs were prepared in RIPA lysis and extraction buffer (\#89901 ThermoFisher Scientific) containing protease and phosphatase inhibitor cocktail (Millipore Sigma). Protein concentration was determined using Pierce BCA Protein Assay Kit (\#23225 ThermoFisher Scientific) and equal amounts (30 μg) of protein lysates were subjected to SDS-PAGE using gradient 4--12% NuPAGE Bis-Tris gels (\#NP0321 Invitrogen) and transferred to 0.2 mm nitrocellulose membranes using Power Blotter Select Transfer Stacks (\#PB3310 ThermoFisher Scientific).

Membranes were blocked with 5% Bovine Serum Albumin (\#A2153 Sigma-Aldrich) in TBST. Osteogenic and Histone deacetylation markers were detected using specific primary antibodies ([Table 1](#t0005){ref-type="table"}). Bound antibodies were visualized with Pierce ECL detection system (\#32106 ThermoFisher Scientific) on Amersham Imager 600 (GE Healthcare, Pittsburgh, PA). The intensity of immunoreactive bands was quantified using Image Lab (Bio-Rad, Hercules, CA).Table 1Specific antibodies used for WB protein analysis.Table 1ProteinAntibody companyCatalog no.β-ActinSigma-AldrichA2228Hdac3AbcamAb7030H4Cell Signaling2935PAcetyl-H4Cell Signaling8647PRunx2Abcamab76956

2.8. Quantitative real time polymerase chain reaction (qRT-PCR) {#s0050}
---------------------------------------------------------------

The levels of 18S, CXCL12, CXCR4, ACKR3, IDO-1 and AhR mRNA in human cells undergoing various treatments were assessed using quantitative real-time PCR and TaqMan reagents. Total RNA was isolated from BMSCs and then purified using the RNAeasy kit (\#74106 Qiagen, SantaClarita, CA). Purified total RNA was reverse transcribed with High-Capacity cDNA Kits (\#4368814 USA -- Applied Biosystems). PCR reactions were performed using TaqMan Fast Advanced Master Mix (\#4444556 USA -- Applied Biosystems). The pre-formulated assay primers used in this study were individual gene-expression assays (\#A25576 Applied Biosystems) ([Table 2](#t0010){ref-type="table"}). 18S was used as the endogenous control for mRNA. The target gene was normalized using the endogenous control to calculate ∆∆Ct values. For real-time PCR, 2 μL of the cDNA sample (100 ng/reaction), 10 μL TaqMan Fast Advanced Master Mix, and 1 μL primer assay were mixed with 7 μL nuclease-free water. All PCR reactions were performed in duplicate.Table 2TaqMan mRNA and miRNA pre-formulated gene specific primer assay IDs.Table 2GeneAssay ID/cat. no.18SMm03928990CXCL12Mm00445553_m1CXCR4Mm1996749ACKR3Mm02619632_s1IDO-1Mm00492590_m1AhRMm00478932_m1miR-29b-1-5pMmu-482721_mirmiR-29b-1-3pMmu481300_mirU6 snRNACat. no. 4427975Hs-RNU6Cat. no. MS00033740

Gapdh, Hdac3, Hsd11b1, NcoR1, and RUNX2 mRNA levels were assessed using quantitative real-time PCR and SYBR Green reagents. Mouse cells cultured in 6-well plates for 7 days were lysed using TRIzol reagent (\#15596-018 Invitrogen), and total RNA was extracted using protocols as previously described. Purified mRNA extracts were reverse transcribed (RT; Bio-Rad C1000 Thermal Cycler, California, USA) to cDNA using commercially available SuperScript III First-Strand Synthesis RT reagents (\#11752-050 Invitrogen). Gene expression was determined by real-time semi-quantitative PCR analysis (qPCR; Bio-Rad CFX Connect PCR System, California, USA) using 37.5 ng of cDNA per 15 μL well volume with QuantaBio PerfeCTa SYBR Green Supermix (\#95054-500 VWR) and SYBR Green gene specific primers ([Table 3](#t0015){ref-type="table"}). Gene expression levels were quantified using the comparative threshold cycle (2^-∆∆Ct^) method. Transcript levels were normalized to the reference gene Gapdh.Table 3SYBR Green mRNA gene specific primer sequences.Table 3GeneForward sequenceReverse sequenceGapdhGGGAAGCCCATCACCATCTTGCCTCACCCCATTTGATGTTHdac3GCATTCGAGGACATGGGGAATTTCGGACAGTGTAGCCACCHsd11b1ACTCAGACCTCGCTGTCTCTTGGGTCATTTTCCCAGCCAANcoR1TTATCGGAGCCACCTACCCACAGGTAAGCAGCAGCAGGATRUNX2GGCACAGACAGAAGCTTGATGAGAATGCGCCCTAAATCACTGA

Murine miR-29b-1-5p and miR-29b-1-3p levels were assayed using the TaqMan reagents mentioned above and the results were normalized to U6 snRNA (USA -- Applied Biosystems). For human miRNA analysis, the expression levels of miR-29b-1-5p and miR-29b-1-3p were measured by miScript qPCR and were normalized to RNU-6 expression (Qiagen, SantaClarita, CA). The catalog numbers for different TaqMan and SYBR green primers are listed in [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, respectively.

2.9. KYN enzyme linked Immunosorbent assay (ELISA) {#s0055}
--------------------------------------------------

Murine bone marrow derived mesenchymal stem cells (BMSCs) of 6 and 18 month old were seeded separately in 6-well flat bottom plates (100,000 cells/well). The cells were grown in DMEM media supplemented with 10% fetal bovine serum and 1× of Antibiotic/Antimycotic Solution (\#15240062 Invitrogen) at 37 °C, 5% CO2 incubator. After 24 h and 48 h of incubation, a media sample was collected from each cell line, centrifuged for 20 min at 1000 ×*g* at 4 °C, transferred to new tube and stored in −80 °C until used. Kynurenine (KYN) ELISA Kit (\#E4629 Biovision, Milpitas, CA) was used to measure kynurenine concentration in media samples by following the manufacturer\'s instructions.

2.10. CXCL12α enzyme linked Immunosorbent assay (ELISA) {#s0060}
-------------------------------------------------------

CXCL12α was measured as described previously ([@bb0070]; [@bb0185]). Briefly, the CXCL12 capture antibody (R&D Systems, Minneapolis, MN) was incubated in sodium bicarbonate buffer overnight. Plates were blocked for 2 h with 1% bovine serum albumin (BSA) in PBS next day. Murine CXCL12α standards and samples were incubated for 2 h before incubating with the biotinylated anti-CXCL12α detection antibody (\#MAB350 R&D Systems). Streptavidin-horseradish peroxidase (HRP) (\#DY998 R&D Systems) was incubated for 20 min followed by the substrate reagent (\#DY999 R&D Systems) for 20 min. 2 N sulfuric acid was added to stop the enzymatic color reaction and absorbance was read at 450 nm. CXCL12α protein expression was calculated using standard curves and normalized to total protein, which was quantified using the Pierce BCA Protein Assay Kit. For age-related CXCL12 plasma and bone marrow interstitial fluid levels one set of male C57BL/6 mice from six different age groups (3, 6, 12, 18, 24, and 29 months of age), 10 mice per age group, were obtained from the aged rodent colony at the National Institute on Aging. Our sample is therefore a cross-sectional as opposed to a longitudinal one. Mice were housed individually and all were fed ad libitum on NIH31 diet. Blood was collected via cardiac puncture once mice were euthanized, as per the IACUC protocol, in EDTA tubes which were centrifuged as previously described to obtain plasma, and stored frozen at −80 °C. Humeri and tibiae were collected to isolate bone marrow interstitial fluid via flushing of the bone marrow space as previously described ([@bb0185]; [@bb0195]; [@bb0115]).

2.11. Mimic and inhibitor miRNA transfection and AhR inhibition {#s0065}
---------------------------------------------------------------

BMSCs were transfected with either a mimic or inhibitor (antagomir) for miR-29b-1-5p (Cat \#YM00471910 and \#YI04101505 Qiagen, SantaClarita, CA) according to the manufacturer\'s protocol. The recommended controls for miR-29b-1-5p mimic and inhibitor were used (Cat \#YM00479902 and Cat \#YI00199006 In brief, cells were seeded at 25,000--30,000 cells/well in a 24-well plate in 500 μl of an appropriate culture medium containing 10% serum and no antibiotics. For 1--3 h until transfection, cells were incubated under normal growth conditions (typically 37 °C and 5% CO~2~). miRNA mimics or inhibitors were resuspended prior to transfection in RNase-free water to achieve the recommended concentration of 20 μM. The miRNA inhibitor and mimic were diluted in Opti-MEM media to give a final miRNA inhibitor concentration of 100 nM and final miRNA mimic concentration of 1 nM for normal transfection experiments and 5 nM for 3′-UTR luciferase assays. HiPerFect transfection reagent (\#301705 Qiagen, SantaClarita, CA) was added to the diluted miRNA mimic/inhibitor and mixed by vortexing. Then, the samples were incubated for 5--10 min at room temperature (15--25 °C) to allow the formation of transfection complexes. The complexes were added drop-wise onto the cells. BMSCs were incubated with the transfection complexes under their normal growth conditions for 6 h, and then the transfection media was removed and replaced with serum-free media containing the desired treatment. Cell culture media samples were collected for analysis, and cells were lysed and mRNA collected at the end of the incubation period. Negative control miR inhibitor was used as a negative control for miR-29b-1-5p inhibitor, and AllStars Hs Cell Death Control siRNA was used as a negative control for miR-29b-1-5p mimic. For AhR inhibition, AhR antagonist, CH-223191 (\#C8124 Sigma-Aldrich) was dissolved in DMSO to make a 2 mg/mL stock solution, and a final concentration of 2 μg/mL was added to BMSCs culture medium ([@bb0020]; [@bb0560]). A second AhR antagonist, 3′,4′-dimethoxyflavone (DMF) (\#D6571 Sigma-Aldrich), was also used (10 μM).

2.12. Luciferase assay {#s0070}
----------------------

Culture-expanded human BMSCs were co-transfected with a either wild type or mutated miTarget miRNA 3′-UTR luciferase functional reporter plasmid for CXCL12 or Hdac3 (\#HmiT088617-MT06 and \#HmiT115117-MT06 GeneCopeia, Rockville, MD) and either miR-29b-1-5p mimic or mimic control (\#YM00471910 and \#YM00479902 Qiagen, SantaClarita, CA) using Lipofectamine 3000 reagent (\#L3000015 ThermoFisher Scientific, Waltham, MA). Mutated plasmids for CXCL12 (at 3 predicted target sites) and Hdac3 (at one predicted target site) were custom made and purchased from Genecopeia (Rockville, MD). The predicted binding sites for miR-29b-1-5p were determined using the prediction software and database MiRanda ([@bb0040]). Dual luciferase activity of the CXCL12 and Hdac3 reporter plasmids were measured 24 h after transfection using Luc-Pair™ Duo-Luciferase High Sensitivity Assay Kit (\#LF004 GeneCopeia, Rockville, MD) according to the manufacturer\'s protocol, and compared to non-targeting miR-transfected controls. The Duo-Luciferase HS Assay Kit was used because it eliminates the need for separate controls to determine if differences are due to differential vector uptake and to normalize the outcomes, e.g. the use of beta-galactosidase which is typically used for normalization to luciferase counts. This is done by including Firefly luciferase (FLuc) and Renilla luciferase (RLuc), where the RLuc signal is used as a control for how much construct was taken into the cell while FLuc signal is used for measuring transcriptional activation. The final signal is expressed as FLuc to RLuc ration to compensate for different transfection efficiencies.

2.13. Statistical analysis {#s0075}
--------------------------

Experiments were performed at least three independent times. Data are expressed as means ± SD unless stated otherwise. Data were analyzed using GraphPad Prism 7.0 software (GraphPad Software Inc., La Jolla, CA, USA). Student *t*-test was used for comparisons between two groups and analysis of variance (ANOVA) followed by Tukey\'s multiple comparison test was used for comparisons between 3 or more groups. Null hypotheses were rejected at the 0.05 level. Statistical significance was determined and shown in figures and figure legends.

3. Results {#s0080}
==========

3.1. CXCL12 axis is downregulated with both aging and KYN treatment in murine and human BMSCs {#s0085}
---------------------------------------------------------------------------------------------

We previously showed that CXCL12 is essential in BMSC osteogenesis ([@bb0185]; [@bb0200]). We also established that KYN contributes to skeletal aging mechanisms and affects the balance between osteogenic and adipogenic differentiation in BMSCs ([@bb0425]). For our initial experiment, we compared the effects of both aging and KYN on the CXCL12 axis. First, we utilized an established ELISA to measure CXCL12 protein levels in murine samples from bone marrow interstitial fluid and plasma at different ages of C57BL/6J mice (*n* = 10 per group). Levels of CXCL12 significantly declined with aging in bone marrow interstitial fluid starting around 12 months of age, while significantly rising in the peripheral circulation after that same age ([Figs. 1](#f0005){ref-type="fig"}A, B). The rise in plasma CXCL12 was similar to what we previously observed in human plasma ([@bb0070]), while the decrease in CXCL12 levels in BM interstitial fluid in aged subjects was similar to our previous BM results in mice ([@bb0395]). Interestingly, in our in vitro system, BMSCs isolated from 18 months old mice showed significantly increased levels of KYN in their cell culture media compared to BMSCs isolated from 6 months old mice after 48 h of incubation ([Fig. 1](#f0005){ref-type="fig"}C).Fig. 1Aging and kynurenine downregulate CXCL12 axis. (A) CXCl12 protein levels in murine plasma from 3, 6, 12, 18, 24, and 29 months-old mice (*n* = 10). (B) CXCl12 protein levels in murine bone marrow interstitial fluid from 3, 6, 12, 18, 24, and 29 months-old mice (n = 10 mice per group). (C) Kynurenine level (μM) in cell culture media of BMSCs isolated from 6 and 18 months old mice (*n* = 3). (D,E) mRNA levels of CXCL12 (D) and CXCR4 (E) in BMSCs isolated from 6, 11, and 27 months-old mice (*n* = 4 for 6 and 11 months old mice and *n* = 7 for 27 months old mice). (F) CXCL12 protein levels in BMSCs isolated from pooled 6 months-old mice after treatment with 200 μM kynurenine for 48 h (n = 4). (G-I) mRNA levels of CXCL12 (F), and CXCR4 (G) and ACKR3 (H) after treatment with 50 and 200 μM kynurenine for 6 h (n = 3). Data presented as mean ± SD. Data analysis was done using one way ANOVA for panels A, B, D, E, F, G, H, and I, and using unpaired *t*-test for panel C. Data presented as mean ± SD. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.Fig. 1

We also assessed how mRNA expression of CXCL12 and its main receptor, CXCR4, changed in BMSCs with aging. We used BMSCs isolated from mice at the ages of 6, 11, and 27 months. These ages correspond to adult (6 months), adult near the peak accumulation of bone mass prior to bone loss (11 months), which is prior to significant changes in CXCL12 protein levels in the BM interstitial fluid, and elderly (27 months), at which time there is significant age-associated bone loss and a significant reduction in BM interstitial fluid CXCL12 ([@bb0175]; [@bb0425]). CXCL12 mRNA levels significantly declined to 50% at 27 months, while CXCR4 mRNA levels were significantly reduced earlier at both 11 and 27 months of age compared to 6 month-old mice ([Figs. 1](#f0005){ref-type="fig"}D, E).

Since KYN levels are linked to aging, we then tested if KYN treatment of BMSCs had a similar effect. BMSCs isolated from 3-, 6-, and 18-month-old mice showed significantly lower CXCL12 protein levels in the cell culture media upon treatment with 200 μM KYN compared to control. CXCL12 protein secreted in culture media from BMSCs isolated from young mice (6 months) was significantly reduced, almost 80%, when treated for 48 h with 200 μM KYN ([Fig. 1](#f0005){ref-type="fig"}F). Secretion of CXCL12 from BMSCs of 3 and 18 months old mice was also decreased with KYN (Supp. Figs. 1A,B). Consistently, there was a significant decrease in CXCL12 mRNA expression in the BMSCs as early as 6 h after treatment. Concomitant with reduction in CXCL12 expression, mRNA expression of the receptors, CXCR4 and CXCR7, was also decreased by almost 30--50% ([Fig. 1](#f0005){ref-type="fig"}G--I). BMSCs isolated from 6-month-old mice showed similar changes in CXCL12 mRNA expression at later time points with a significant decrease at 48 h post-treatment (Supp. Fig. 1C).

3.2. KYN attenuated osteogenesis and osteogenic gene expression in BMSCs {#s0090}
------------------------------------------------------------------------

In vivo experiments have shown that KYN accumulates with aging and induces bone loss ([@bb0425]). To establish if, at least in part, KYN achieves this function via inhibition of BMSC osteogenesis, we treated BMSCs isolated from 6- and 18-month-old mice with different doses of KYN (10, 50, 200 μM). Using osteogenic differentiation media for 21 days and Alizarin Red staining, KYN doses inhibited osteogenic differentiation in BMSCs from 6-month-old mice in a dose dependent manner, with the high KYN dose (200 μM) showing a significant 50% decrease ([Fig. 2](#f0010){ref-type="fig"}A). After 14 days, the high KYN dose also showed significant inhibition of minerlization with Alizarin Red staining (Supp. [Fig. 2](#f0010){ref-type="fig"}A), as well as intermittent doses (Supp. [Fig. 2](#f0010){ref-type="fig"}D). The early effects of KYN on osteogenic differentiation of BMSCs isolated from 6 months old mice were confirmed using alkaline phosphatase activity assay after 7 days of incubation in osteogenic differentiation media ([Fig. 2](#f0010){ref-type="fig"}B). To determine whether this KYN effect was in fact due to inhibition of osteogenesis and not an effect on cell density, a crystal violet assay assessed KYN cytotoxicity and showed that none of the doses of KYN (10. 50, and 200 μM) affected cell proliferation as determined by the number of BMSCs when cultured under the same conditions as the osteogenic differentiation experiments (Supp. Fig. 2C).Fig. 2Kynurenine inhibits BMSCs osteogenic differentiation. (A) Optical density of alizarin red osteogenic assay staining and corresponding wells of BMSCs isolated from pooled 6 months-old mice after treatment with different doses of kynurenine (10, 50, and 200 μM) for 21 days (*n* = 6). (B) Alkaline Phosphatase (ALP) activity relative to control in BMSCs isolated from pooled 6 months-old mice treated with different doses of kynurenine (10, 50, and 200 μM) for 7 days (n = 6) (C) mRNA levels of Runx2 in BMSCs isolated from young (6--8 months-old) and old (22--24 months-old) mice, in osteogenic differentiation medium with or without 200 μM kynurenine for 7 days (n = 3 mice per group). (D) Protein levels of Runx2 in BMSCs isolated from 6 months mice after incubation in osteogenic differentiation medium with or without 200 μM kynurenine for 7 days. Data presented as mean ± SD. Data analysis was done using one way ANOVA for panels A, B, and C, and using unpaired t-test for panel D. \*P \< 0.05, \*\*P \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.Fig. 2

Next, directly isolated BMSCs (i.e., without in vitro expansion/passaging prior to experimentation) from young and old mice (6--8 months versus 22--24 months) were used to assess how KYN affects their osteogenic differentiation marker expression. Basal expression level of the osteogenic marker, Runx2 was significantly lower in osteogenically-cultured BMSCs isolated from old mice compared to similarly cultured BMSCs isolated from young mice. We also found that treating BMSCs from either younger or older mice with KYN significantly reduced their mRNA levels of Runx2, resembling the effect of aging. Runx2 protein expression was also significantly downregulated after 7 days of KYN treatment in osteogenic differentiation media ([Fig. 2](#f0010){ref-type="fig"}C, D).

3.3. The KYN treatment phenotype resembles aging in upregulating CXCL12-targeting miR-29b-1-5p {#s0095}
----------------------------------------------------------------------------------------------

To determine how in vitro administration of KYN induced a phenotype reminiscent of organismal aging in terms of miR-29b-1 expression, we measured miR-29b-1-5p levels in BMSCs from young versus old mice. BMSCs isolated from aged mice had significantly higher levels of miR-29b-1-5p and significantly lower levels of miR-29b-1-3p compared to BMSCs from younger mice ([Fig. 3](#f0015){ref-type="fig"}A, B). As in the mice we also found that miR-29b-1-5p levels in aged human MSCs were significantly upregulated in aged vs. adult MSCs, but different from the murine the miR-29b-1-3p levels were not significantly changed in humans with age (Supp. Fig. 3A).Fig. 3Kynurenine upregulates pro-aging and CXCL12-targeting miR-29b-1-5p. (A,B) miR-29b-1-5p (A) and miR-29b-1-3p (B) levels in BMSCs isolated from 11 versus 27 months old (n = 4 for 11 months old mice and n = 7 for 27 months old mice). (C,D) miR-29b-1-5p levels (C) and miR-29b-1-3p levels (D) in BMSCs isolated from pooled 6 months-old mice after treatment with 200 μM kynurenine for 1, 3, 6, 24 and 48 h (n = 3). (E,F) CXCL12 levels in BMSCs isolated from 6 months old mice after treatment with 200 μM kynurenine with or without transfection with miR-29b-1-5p inhibitor (E) or miR-29b-1-5p mimic (F) (*n* = 8 for inhibitor and n = 4 for mimic). (G) Luciferase activity of CXCL12 reporter plasmids (wild type and mutant) after transfection with miR-29b-1-5p mimic relative to luciferase activity of wild type CXCL12 reporter plasmid after transfection with miRNA mimic control for 24 h (n = 3). Data presented as mean ± SD. Data analysis was done using one way ANOVA for panels E, F amd G, using two way ANOVA for panels C and D, and using unpaired t-test for panels A and B. \*P \< 0.05, \*\*P \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.Fig. 3

We then measured miR-29b-1-5p levels in murine BMSCs from 6-month-old mice with or without KYN treatment for 1, 3, 6, 24, and 48 h. KYN transiently, upregulated miR-29b-1-5p beginning at 24 h ([Fig. 3](#f0015){ref-type="fig"}C). The levels of miR-29b-1-5p expression in response to KYN was almost back to normal by 48 h.

To confirm that increased levels of miR-29b-1-5p mediated KYN\'s effect on the CXCL12 axis, rather than being an independent downstream effect of KYN, we transfected BMSCs isolated from 6-month-old mice with a miR-29b-1-5p inhibitor, and treated them with KYN for 24 h. The miR-29b-1-5p inhibitor alone did not significantly upregulate CXCL12 protein level when there was low basal levels of miR-29b-1-5p to start with. However, it restored CXCL12 protein levels when combined with 200 μM KYN, which by itself increased miR-29b-1-5p and significantly downregulated CXCL12 protein levels ([Fig. 3](#f0015){ref-type="fig"}E). We further confirmed this result by treating the same BMSCs with 200 μM KYN in the presence or absence of the miR-29b-1-5p mimic. Consistently, both KYN and the miR-29b-1-5p mimic significantly downregulated CXCL12 protein levels by almost 30%. Further, combining both miR-29b-1-5p and KYN together lead to a significant almost a 40% inhibition of the CXCL12 protein level ([Fig. 3](#f0015){ref-type="fig"}F).

To determine whether miR-29b-1-5p\'s effect on CXCL12 was direct or indirect, we utilized a 3′-UTR Duo-Luciferase assay, which controls for vector uptake and transcriptional regulation in the same assay. A reporter plasmid for wild type CXCL12 3′-UTR and another reporter plasmid for CXCL12 3′-UTR mutated at all three potential binding sites for miR-29b-1-5p according to the target prediction database Miranda ([@bb0360]) ([Table 4](#t0020){ref-type="table"}) were used to assess whether the miR-29b-1-5p directly targets the predicted binding sites. Transfection of murine BMSCs with the miR-29b-1-5p mimic resulted in a significant reduction (almost 30%) in the luciferase activity of the CXCL12 reporter plasmid. When the wild type CXCL12 3′-UTR was replaced with the mutated CXCL12 3′-UTR, the luciferase activity was significantly increased indicating that miR-29b-1-5p could not bind and inhibit CXCL12 luciferase activity ([Fig. 3](#f0015){ref-type="fig"}F).Table 4Sequences of predicted binding sites between miR-29b-1-5p and the 3′-UTR of Hdac3 and CXCL12 according to MiRanda database. The miR-29b-1-5p sequence is the top of each pairing.Table 4Target accessionScoremiRNA start-end3′utr start-end3′-miRNA-5′-alignment-5′-utr3-3′Hdac3 (NM_001355039)122.002--2383--106![](t1.gif)CXCL12 (NM_000609)163.002--2232--54![](t2.gif)CXCL12 (NM_000609)151.003--222858--2880![](t3.gif)CXCL12 (NM_000609)141.002--23558--582![](t4.gif)

3.4. KYN and miR-29b-1-5p differentially modulated Hdac3 levels {#s0100}
---------------------------------------------------------------

We previously demonstrated that administration of KYN in vivo downregulates the levels of Hdac3 as well as its cofactor NCoR1 ([@bb0425]). We further showed that Hdac3 plays an important role in the regulation of osteogenic and adipogenic differentiation in BMSCs in aging ([@bb0425]; [@bb0420]). Here, we measured the basal mRNA levels of Hdac3 and its cofactor NcoR1 in BMSCs isolated from young adult mice versus old mice. When BMSCs were grown in osteogenic differentiation medium for 7 days, the mRNA levels of these two markers were downregulated in murine BMSCs with aging. In addition, treatment with KYN significantly downregulated mRNA levels of both markers in young and old mice ([Fig. 4](#f0020){ref-type="fig"}A, B).Fig. 4Kynurenine downregulates Hdac3 and its cofactors. (A,B) mRNA expression levels of (A) Hdac3 and (B) NcoR1 in BMSCs isolated directly from young and old mice and cultured in osteogenic differentiation medium with or without 200 μM kynurenine for 7 days (n = 3). (C,D) mRNA expression levels of Hdac3 in BMSCs isolated from pooled 6 months-old mice and transfected with either (C) miR-29b-1-5p mimic or (D) miR-29b-1-5p inhibitor compared to their respective controls (n = 3). (E) Luciferase activity of Hdac3 reporter plasmids (wild type and mutant) after transfection with miR-29b-1-5p mimic relative to luciferase activity of wild type Hdac3 reporter plasmid after transfection with miRNA mimic control for 24 h (n = 3). (F,G) Protein levels of Hdac3 (F) and H4 acetylation (G) in BMSCs isolated from pooled 6 months-old mice after incubation in osteogenic differentiation medium with or without 200 μM kynurenine for 7 days. Data presented as mean ± SD. Data analysis was done using one way ANOVA for panel E, using two way ANOVA for panels A and B, and using unpaired t-test for panels C, D, F, and G. \*P \< 0.05, \*\*P \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.Fig. 4

To establish the relationship between miR-29b-1-5p levels and Hdac3 levels, we measured Hdac3 mRNA expression in cells transfected with either the miR-29b-1-5p mimic or the miR-29b-1-5p inhibitor. Consistently, miR-29b-1-5p mimic significantly downregulated, while miR-29b-1-5p inhibitor significantly upregulated, Hdac3 mRNA levels ([Fig. 4](#f0020){ref-type="fig"}C, D).

To determine whether the effect of miR-29b-1-5p on Hdac3 is direct or indirect, we designed another 3′-UTR Duo-Luciferase assay using wild type and mutated Hdac3 3′-UTR vector plasmids. We found that miR-29b-1-5p significantly reduced luciferase activity for the wild type Hdac3 3′-UTR, and had no effect on the mutated Hdac3 3′-UTR, confirming that miR-29b-1-5p acts directly on Hdac3 via the predicted binding site (Miranda database) ([@bb0360]) ([Fig. 4](#f0020){ref-type="fig"}E) ([Table 4](#t0020){ref-type="table"}).

We also measured Hdac3 protein expression and H4 acetylation levels in response to 200 KYN μM or miR-29b-1-5p mimic to confirm our previous results and found that consistent with our mRNA data, both KYN and miR-29b-1-5p inhibited Hdac3 protein levels and we demonstrated the expected downstream functional effect of Hdac3 suppression as evidenced by the significant increase in H4 acetylation ([Fig. 4](#f0020){ref-type="fig"}G, H).

3.5. AhR mediates the effects of KYN on CXCL12 {#s0105}
----------------------------------------------

KYN has been shown to act through binding to the aryl hydrocarbon receptor (AhR), which then translocates to the nucleus ([@bb0035]). We tested if the AhR receptor was mediating KYN\'s effects on CXCL12 protein levels, and on CXCL12, CXCR4, and ACKR3 mRNA levels. We utilized the AhR antagonist 3′,4′-dimethoxyflavone (DMF), and found that after 48 h of treatment, KYN significantly reduced secreted CXCL12 in the cell culture media of BMSCs from 6-month-old mice, and that co-treatment with DMF was able to restore CXCL12 protein level ([Fig. 5](#f0025){ref-type="fig"}). Of translational importance, KYN treatment (50 and 200 μM) downregulated secreted CXCL12 from human BMSCs level and the AhR antagonist CH-223191 restored it within 24 h (Supp. Fig. 2B).Fig. 5AhR antagonist inhibits kynurenine-induced CXCL12 downregulation. CXCL12 protein levels in BMSCs isolated from pooled 6-month-old mice after treatment for 48 h with 100 or 200 μM kynurenine with or without 10 μM of AhR-antagonist 3′,4′-Dimethoxyflavone (DMF) (n = 3). Data presented as mean ± SD. Data analysis was done using unpaired t-test. \*\**P* \< 0.01.Fig. 5

3.6. CXCL12 regulates IDO-1 and AhR mRNA levels {#s0110}
-----------------------------------------------

To test whether there was cross-talk between CXCL12 and KYN whereby CXCL12 could suppress KYN-related pathways, we treated BMSCs isolated from 6-month-old mice with 200 ng/mL CXCL12. Ttreatment with CXCL12 significantly downregulated the mRNA levels of AhR after 6 h and IDO-1, the gene encoding an enzyme that can generate KYN, after 24 h suggesting that cross-talk exists ([Fig. 6](#f0030){ref-type="fig"}A, B).Fig. 6CXCL12 regulates mRNA levels of IDO-1 and AhR. (A,B) mRNA expression levels of (A) IDO-1, and (B) AhR after treatment with CXCL12 (200 ng/mL) for 24 and 6 h respectively (n = 4). Data presented as mean ± SD. Data analysis was done using one way ANOVA for panel C, and using unpaired t-test for panels A and B. \*P \< 0.05, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.Fig. 6

4. Discussion {#s0115}
=============

Tryptophan metabolism directly through the KYN pathway is involved in the regulation of key physiological functions such as immunity, CNS/neuronal function, gastrointestinal homeostasis and we now recognize in bone metabolism. Metabolic dysregulation in disorders affecting these areas including aging, cancer, and neurodegenerative disease have led to significant clinical-translational interest and even clinical trials targeting the KYNP pathway, specifically KYN, its downstream metabolites and the AhR signaling pathway that responds to KYN and its metabolites ([@bb0405]). Based on our work, and that of others, it is now clear that this system is also critically involved in osteoporosis and age-related bone loss. Here we help delineate the mechanisms linking KYN and bone loss.

Osteoporosis is a bone disease characterized by a decrease in the ratio of bone formation to bone resorption with aging. Osteoporosis is mostly asymptomatic during the first few years which makes early diagnosis more difficult ([@bb0400]). Currently available treatments for osteoporosis can be associated with a wide range of side effects ([@bb0010]). A key barrier to preventing osteoporosis or developing efficient new treatments is understanding the mechanisms underlying the aging-related deterioration in bone health and subsequent progression of osteoporosis. Our group and others have demonstrated that osteoporosis is - at least in part - a stem cell disease ([@bb0215]; [@bb0200]; [@bb0010]). This study aimed to investigate molecular pathways triggering age-associated changes in the bone marrow stem cell populations that could lead to osteoporosis and thus may represent a new therapeutic target.

Osteogenic differentiation is critical in bone aging; as we age, there is a shift in BMSCs from osteogenic to adipogenic differentiation ([@bb0215]). Our group and other groups have reported the beneficial role of CXCL12α and β in the osteogenic differentiation of BMSCs ([@bb0555]; [@bb0190]; [@bb0200]). We have found that increased KYN levels, as well as an elevated KYN to TRP ratio, contribute to reductions in BMSCs osteogenesis and subsequent decreased bone formation in association with aging ([@bb0130]; [@bb0255]). We have previously reported increased serum and bone marrow levels of KYN with aging in humans ([@bb0425]) ([@bb0255]). While the specific mechanism of age-related increases in KYN levels in different tissue compartments is still not fully understood, the elevated KYN levels may be due to upregulated local IDO activity with aging, as well as increased ROS mediated conversion of tryptophan to KYN. These, or potentially other mechamisms can lead to higher KYN levels and an increase in the KYN/TRP ratio ([@bb0485]; [@bb0455]). KYN also downregulates Hdac3 and its cofactor NcoR1 which increases the degree of adiposity in murine bone marrow together with reducing bone mass ([@bb0425]). We also recently assessed an array of miRNAs that are upregulated in human BMSCs with aging, identifying miR-29b-1-5p as a key miRNA involved in inhibiting osteogenesis with age ([@bb0205]; [@bb0390]; [@bb0025]; [@bb0280]; [@bb0495]; [@bb0470]; [@bb0300]; [@bb0540]; [@bb0385]). Here, we investigate how these different anti-osteogenic pathways interact, underscoring new biomarkers that can be targeted for clinical intervention to prevent or treat osteoporosis at the stem cell level.

Our results here confirm that KYN inhibits BMSC osteogenesis and downregulates osteogenic gene expression. This is in agreement with work from Dinçel et al., who showed a significant correlation between a high KYN/TRP ratio and the incidence of osteoporotic hip fracture ([@bb0110]). We have also shown that KYN levels and the KYN/TRP ratio in the human bone marrow microenvironment are increased with age ([@bb0255]). More importantly, we showed that subjects with increased bone fragility, marked by decreased total femur BMD and increased markers of bone resorption, have significantly higher KYN levels and KYN/TRP ratios than those without ([@bb0255]). Another group demonstrated that high levels of peripheral KYN and AhR are significantly correlated with decreased bone strength, in contrast high central KYN levels in the frontal cortex of the brain are correlated with increased bone strength ([@bb0225]; [@bb0230]). These investigators believe that similar to serotonin, another TRP metabolite, KYN can exert opposing effects on bone formation depending on its site of action ([@bb0230]; [@bb0125]).

The identification of mechanisms underlying KYN\'s anti-osteogenic effects has been limited. Here, we demonstrate potential novel mechanisms based on downregulation of CXCL12 axis mRNA expression and protein levels, via KYN ligand signaling through the AhR and mediated by epigenetic changes in miRNAs and Hdac3. The decrease in CXCL12 protein levels in response to KYN treatment and our previous findings indicating that CXCL12 is important for osteogenesis, in turn support the theory that KYN inhibits BMSCs osteogenesis via downregulation of the CXCL12 axis. We also found that KYN-mediated downregulation of CXCL12 mimics the decline in CXCL12 protein levels in human and murine bone marrow interstitial fluid with aging. The reason for the corresponding age-related increase in CXCL12 levels in murine and human plasma is not clear, but it could be due to summing of inflammatory responses throughout the body in the plasma, or to regulated compartmentalized changes in CXCL12 expression that are different in the bone marrow versus plasma, and/or to an accumulation of DPP4-cleaved non-CXCR4-activating CXCL12 in plasma subsequent to feedback ([@bb0070]; [@bb0115]; [@bb0135]). Recently, links between AhR signaling and both CXCR4 and ACKR3 levels have been suggested, where high AhR expression was correlated with high expression of CXCR4 in breast tumors ([@bb0515]), and hepatic toxicity in response to AhR activation was mediated, at least in part, by changes in ACKR3 mRNA levels ([@bb0535]). Another potential link between the KYN pathway and the CXCL12 axis, is the reported IDO- and tryptophan-mediated regulation of CXCR4 expression and responsiveness to chemokines in dendritic cells ([@bb0210]).

KYN may achieve its anti-osteogenic effects in part by upregulating miR-29b-1-5p, which targets CXCL12 and other osteogenic genes. We noticed that changes in miR-29b-1-5p in response to KYN treatment of 200 μM peaked around 24 h and was almost back to basal level by 48 h, which is expected due to the transient on/off nature of miRNA regulation ([@bb0030]; [@bb0580]; [@bb0445]). This miRNA upregulation supports the idea that increased KYN levels with age may be a key regulator of the age-associated decrease in osteogenesis. In this study, we focused mainly on miR-29b-1-5p since, it targeted both CXCL12 and Hdacs, a second distinct epigenetic regulatory system. We had in silico evidence that miR-29b-1-5p targets position 278--302 of the Hdac3 3′ UTR ([@bb0360]). We confirmed here, for the first time that this miRNA directly targets and down-regulates both Hdac3 and CXCL12. Whether KYN can downregulate CXCL12 independently from miR-29b-1-5p is yet to be determined. We found that KYN\'s effect on the CXCL12 protein level is attenuated by the use of a miR-29b-1-5p (antagomir) inhibitor and increased by the use of the miR-29b-1-5p mimic. This is further evidence that miR-29b-1-5p is involved in KYN\'s downregulation of CXCL12. This age-associated miRNA upregulation supports the idea that increased KYN levels with age may be a key regulator of the age-associated decrease in osteogenesis and may be linked to aging in other systems.

The effect of KYN on miR29b-1-5p supports results from other groups that miR-29b may play a role in osteoarthritis development through inhibiting the expression of collagen I by chondrocytes and collagen III by BMSCs ([@bb0330]). We also found that miR-29b-1-5p and miR-29b-1-3p levels change in opposite directions in mice with aging. This is interesting, because Feichtinger et al. ([@bb0145]) found that high levels of miR-29b-1-3p are associated with healthy bone microstructure and histomorphometry. In previous work on human BMSCs, we only observed an increase in the miR-29b-1-5p passenger strand with aging without a concomitant decrease in the miR-29b-1-3p guide strand (Supp. Fig. 3C) ([@bb0385]); thus, there may be a difference between human and murine age-associated expression of the guide and passenger strand levels with the regulation of the 5p arm being more critical in aging humans. miR-29b is not the only miRNA bone marker that shows opposing effects of its guide and passenger strands on bone health, as miR-500a-3p was shown to have a positive correlation with bone surface, as well as mineral apposition rate, while miR-500a-5p was shown to play an inhibitory role in osteogenic differentiation and was reported as a novel biomarker for fracture risk in postmenopausal women ([@bb0145]; [@bb0180]). These observations support the idea that in pathologies, including aging, there may be a dysregulation of the microRNA processing leading to significant changes in the targeting of mRNAs.

Importantly, KYN also downregulates Hdac3 and its cofactor NcoR1; an effect that we previously linked to decreased osteogenesis and increased adipogenesis in murine bone marrow ([@bb0425]; [@bb0420]). Hdac3 plays a critical role in the process of endochondral ossification and bone matrix remodeling. Loss of Hdac3 in osteochondral progenitors leads to an osteopenic phenotype from impaired bone formation and increasing marrow adiposity, and postnatal inducible conditional knockout of chondrocyte Hdac3 leads to several skeletal abnormalities as well as increased osteoclastogenesis ([@bb0420]; [@bb0075]; [@bb0160]; [@bb0150]; [@bb0335]). These studies all implicate Hdac3 as a crucial mediator of endochondral ossification, particulary in the context of aging. It is also important to note that Hdac3 plays an important role in adipogenesis, where lower Hdac3 levels correlated with an increase in bone marrow fat ([@bb0420]). This effect could explain the increase in bone marrow adipose tissue we previously reported in mice that received a high KYN diet ([@bb0425]).

We believe that the effects of KYN reported here are primarily, but not necessarily exclusively, mediated through AhR mediated signaling. In other work, it was demonstrated that AhR activation can affect bone health through downstream effects including reduced ossification as well as inhibition of osteogenic differentiation and osteoblast functions ([@bb0570]; [@bb0220]; [@bb0355]). Here, we found that the use of the AhR antagonists DMF and CH-223192 in combination with KYN partially rescued CXCL12 gene and protein expression. The anti-osteogenic action of KYN may be mediated through other pathways as well. Indeed, it was recently reported that KYN can regulate Wnt signaling and inhibit β-catenin expression, which is a key regulatory pathway for osteogenesis and bone formation ([@bb0380]), and miR-29b-1-5p is predicted to potentially target Wnt1. Furthermore, the miR-29b-1-5p mimic significantly upregulated AhR mRNA expression levels, while both the miR-29b-1-5p inhibitor and CXCL12 significantly downregulated those levels and CXCL12 also downregulated IDO-1 expression. This result suggests that either miR-29b-1-5p is upstream of AhR activation, or a feedback regulation mechanism exists between the two, as well as cross-talk between CXCL12 with IDO-1 and AhR, as well as being potentially able to target multiple osteogenic genes. ([Fig. 7](#f0035){ref-type="fig"}).Fig. 7Proposed pathway of kynurenine effects on BMSCs. Aging upregulates activity of IDO1 which converts tryptophan to kynurenine. Kynurenine is then taken up by BMSCs and binds to cytoplasmic AhR. Upon binding, ligand-bound AhR is transported into the nucleus where it forms a complex with Aryl hydrocarbon receptor nuclear translocator (ARNT). The newly formed complex acts as a transcription factor and downregulates Hdac3 and CXCL12 transcription while upregulating miR-29b-1-5p. Hence, the overall effect of kynurenine and AhR complex is shifting from osteogenic to adipogenic differentiation in BMSCs. CXCL12 acts via a feedback regulation mechanism to downregulate IDO1 and AhR mRNA levels, while miR-29b-1-5p upregulates AhR mRNA level.Fig. 7

In summary, we show that KYN contributes to bone aging via AhR activation, which leads to upregulation of miR-29b-1-5p with downregulation of both Hdac3 and CXCL12. These combined effects lead to a reduced osteogenic differentiation capacity in BMSCs, and contributes to the aging-induced decline in bone formation. Whether the effects of KYN are solely mediated via AhR is yet to be determined. We believe that KYN pathway mediators including IDO-1 and AhR, as well as the downstream molecules investigated in this work (CXCL12, Hdac3, and miR29b-1-5p), offer new potential targets for clinical intervention to prevent or treat osteoporosis.

Declaration of competing interest
=================================

Drs. William Hill, Sergio Mas Herrero, and Sudharsan Periyasamy-Thandavanis are inventors on U.S. Patent No. 9,267,139, "Compositions and Methods for Treating Musculoskeletal Disorders" issued. Ahmed Elmansi, Galina Kondrikova, Jessica Pierce, Helen Kaiser, Drs. Khaled Hussein, Xue Jiang, Alexandra Aguilar-Pérez, Dmitry Kondrikov, Nada H. Eisa, Ke-Hong Ding, Aisha Walker, Sadanand Fulzele, Wendy B. Bollag, Mohammed Elsalanty, Qing Zhong, Xing-ming Shi, Yun Su, Maribeth Johnson, Monte Hunter, Charles Reitman, Brian Volkman, Mark Hamrick, Carlos Isales, Meghan McGee-Lawrence have no conflicts of interest or financial ties to disclose.

Appendix A. Supplementary data {#s0130}
==============================

Supplementary Fig. 1. (A,B) Kynurenine at 200 μM significantly downregulates secreted CXCL12 protein level in cell culture media of BMSCs isolated from (A) pooled 3 months-old and (B) pooled 18 months-old mice (n = 4). (C) Kynurenine at 200 μM significantly downregulates CXCL12 mRNA level in BMSCs isolated from pooled 6 months-old mice after 24 and 48 h of treatment (n = 4). Data presented as mean ± SD. Data analysis was done using two way ANOVA for panel C, and using unpaired *t*-test for panels A and B. \*P \< 0.05, \*\*P \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.Supplementary Fig. 2. (A) Kynurenine at 200 μM significantly inhibits early osteogenic differentiation of BMSCs isolated from pooled 6 months-old mice as shown by Alizarin Red staining after 14 days of treatment (n = 6). (B) Kynurenine (50, 100, 200 μM) downregulates CXCL12 level in cell culture media of human BMSCs (74 year-old female) after 24 h of treatment, and AhR antagonist, CH-223191 (2 μg/mL), significantly rescues CXCL12 level with the 50 μM dose (n = 3). (C) Effect of kynurenine at different doses (10, 50, 200 μM) on cell density of BMSCs isolated from pooled 6 months-old mice as shown by crystal violet assay shows no changes in cell density. (D) Optical density of alizarin red osteogenic assay staining and corresponding wells of BMSCs isolated from 6 months-old mice after treatment with different doses of kynurenine (10, 25, 50, 100 μM) for 21 days shows inhibition of osteogenesis at all KYN doses (n = 6). Data presented as mean ± SD. Data analysis was done using one way ANOVA for panel C, using two way ANOVA for panels B and D, and using unpaired *t*-test for panel A. \*P \< 0.05, \*\*P \< 0.01. \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.Supplementary Fig. 3. miR-29b-1-5p is upregulated in culture-expanded human CD271+ BMSCs (passage one) with aging or in response to KYN treatment. Transcript analysis using cultured MSCs and specific miRNA primers showed that miR-29b-1-5p was significantly upregulated in Aged (\>60 year-old) relative to adult (26-59 year-old) human MSCs, while no changes in the mature miR-29b-1-3p were observed. Data are shown as means ± SEM. (n = 7 subjects per age group). \*P \< 0.05.Image 5
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